News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

May 25, 2025

Lipidor applies for bankruptcy

STOCKHOLM, Sweden, 25th May 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company's board has resolved to file for bankruptcy on behalf of the Company. The bankruptcy application will be submitted today, 25th May 2025, to the Stockholm District Court. The decision was…

May 24, 2025

Lipidor announces today negative results from the company’s Phase III clinical study of AKP02G2 for psoriasis

STOCKHOLM, Sweden, 24th May 2025 – (Nasdaq First North: LIPI) reports negative results from a Phase III clinical study of the AKP02G2…

May 19, 2025

Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2

STOCKHOLM, Sweden, 19th May 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III…

May 9, 2025

Lipidor AB (publ) publishes annual report for 2024

STOCKHOLM, Sweden, 9th May 2025 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the…

March 17, 2025

Lipidor announces all patients enrolled in ongoing Phase III study

STOCKHOLM, Sweden, 17th March 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the…

February 28, 2025

Lipidor AB (publ) publishes year-end report for 2024

STOCKHOLM, Sweden, 28th February 2025 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the…

January 21, 2025

Lipidor announces half of patients enrolled in ongoing Phase III study

STOCKHOLM, Sweden, 21st January 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients…

December 3, 2024

Lipidor presents Nomination Committee

STOCKHOLM, Sweden, 3rd December 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall…

November 20, 2024

Lipidor publishes CEO statement for the quarter: “Study results expected by the end of Q1 2025”

STOCKHOLM, Sweden, 20 November 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today provides an update on the business…

September 24, 2024

Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

STOCKHOLM, Sweden, 24 September 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the first patient has…

August 28, 2024

Lipidor AB (publ) publishes interim report for Q2 2024

STOCKHOLM, Sweden, 28 August 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the…